FMP
VolitionRx Limited
VNRX
AMEX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
0.475 USD
-0.0125 (-2.63%)
VNRX Financial Statements
Year
2024
2023
2022
2021
CF from Operating Activities
-25.89M
-18.06M
-15.28M
-20.85M
Net Income
-27.26M
-35.32M
-30.6M
-26.99M
Depreciation & Amortization
1.34M
1.41M
1.19M
1.15M
Deferred Income Taxes
0
0
-4.69M
0
Stock Based Compensation
1.27M
2.29M
3.11M
5.12M
Change in Working Capital
-1.25M
14.14M
11.02M
-156.11k
Accounts Receivable
132.04k
-169.67k
-72.61k
-12.51k
Inventory
0
0
0
-481.86k
Accounts Payable
-1.22M
1.22M
548.61k
534.73k
Other Working Capital
-164.11k
13.08M
10.54M
-196.47k
Other Non-Cash Items
5.97k
-582.46k
4.69M
26.17k
CF from Investing Activities
-573.85k
-1.08M
-1.57M
-973.56k
Investments in Property, Plant & Equipment
-277.5k
-1.08M
-1.57M
-973.56k
Net Acquisitions
0
0
0
0
Investment Purchases
0
0
0
0
Sales/Maturities of Investments
0
0
0
0
Other Investing Activites
-296.35k
0
0
0
CF from Financing Activities
8.66M
28.98M
6.94M
22.86M
Debt Repayment
-47.72k
827.08k
-1.31M
-813.93k
Common Stock Issued
8.59M
28.39M
6.74M
23.22M
Common Stock Repurchased
0
-31.77k
0
0
Dividends Paid
0
0
0
0
Other Financing Activites
-168.15k
-200.66k
-7.69k
-140.58k
Free Cash Flow
-26.17M
-19.15M
-16.85M
-21.83M
Operating Cash Flow
-25.89M
-18.06M
-15.28M
-20.85M
Capital Expenditures
-277.5k
-1.08M
-1.57M
-973.56k
Cash at Beginning of Period
20.73M
10.87M
20.58M
19.44M
Cash at End of Period
3.26M
20.73M
10.87M
20.58M
Net Change In Cash
-17.47M
9.86M
-9.71M
1.14M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-202.58M
-167.26M
-136.99M
-110.17M
Net Income
-26.97M
-35.32M
-30.27M
-26.97M
Stock Repurchases
0
-31.77k
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-229.54M
-202.58M
-167.26M
-136.99M
Other Distributions
-26.97M
-35.35M
-30.27M
-26.81M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
5.03M
6.07M
6.01M
5.29M
Annual Depreciation
1.34M
1.41M
1.19M
1.15M
Capital Expenditure
-277.5k
-1.08M
-1.57M
-973.56k
Net PPE
3.97M
5.74M
6.39M
5.12M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
